Edesa Biotech Inc (EDSA)

$1.19 -0.04 (-3.25%)
Market Cap 9.75M
Revenue (ttm) 0.00
Net Income (ttm) -7.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 35,956
Avg Vol 59,460
Day's Range N/A - N/A
Shares Out 8.33M
Stochastic %K 34%
Beta 0.13
Analysts Strong Sell
Price Target $11.00

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic aller...

Industry: Biotechnology
Sector: Healthcare
Phone: 289 800 9600
Address:
100 Spy Court, Markham, Canada
Treb3k
Treb3k Feb. 2 at 6:57 PM
$EDSA power hour baby LETS GOOOOOOOOOOO
0 · Reply
Treb3k
Treb3k Feb. 2 at 6:57 PM
$EDSA its par buying on open market! confident in his company
0 · Reply
EdV3
EdV3 Feb. 2 at 6:21 PM
$EDSA looking like one of the tutes sold their commons at any price to get out Would explain the large sells and quick rebound after they completed liquidation Other possibility is company crushed the atm..shelf now tapped so share price can stabilize....hopefully
0 · Reply
Moneyybaggs
Moneyybaggs Feb. 2 at 3:57 PM
$EDSA Understand who might be selling, but who in their RIGHT FOOKIN MIND is buying this steaming pile of excrement?!?
0 · Reply
EdV3
EdV3 Feb. 2 at 3:46 PM
$EDSA Maybe ATM, maybe a tute selling last few days. Good bad or ugly something is gonna happen.
0 · Reply
maurizio58
maurizio58 Feb. 2 at 3:21 PM
$EDSA other 450.000 actions
0 · Reply
maurizio58
maurizio58 Feb. 2 at 3:20 PM
$EDSA ATM...!!!!!!
0 · Reply
EdV3
EdV3 Feb. 1 at 8:21 PM
$EDSA Tough to watch the stock price slide into the depths of hell. Probably will get worse. IMO they will not proceed with dosing patients until a strategic partner is lined up, or there is some clear PIPE type financing ready to go. A realistic partnership could look like a small upfront payment of 3-7m with the partner fully funding the P2. Another route could be a co development deal with a larger upfront payment and cost sharing for the trial. A 3rd possibility would be a regional licensing deal (ex NA) with the partner funding a P2 in their market. Honestly, any of those scenarios are realistic and would make a world of difference for shareholders. A "free" P2 for EB06 would resuscitate interest. In parallel I'm sure they are still trying to probe potential pathways for EB05. It comes down now to execution. 7 years since ipo and they've destroyed basically all the value. With their track record, does anyone truly believe they'll be able to pull it off? Hard to say.
0 · Reply
EdV3
EdV3 Feb. 1 at 8:10 PM
$EDSA My guess is they have around 12 mil in cash as of right this moment. I'm assuming they've sold another 500k-700k shares atm since the mid December update so figure the baby shelf has only another mil or so that can be exercised. That means the immediate dilution threat (not withstanding a financing deal which will probably come) is coming to an end. That's a fairly healthy cash position. For them it's around 2 years of runway not accounting for any scaled r&d spend. They will continue to work on putting together a turnkey P2 package which will likely be ready sometime in April or May. They are probably still waiting on drug substance and will soon after submit the necessary package to the FDA. From there the IND should be approved within 30 days unless anything is flagged.
0 · Reply
EdV3
EdV3 Jan. 30 at 9:20 PM
$EDSA When legit companies undergo these valuation overshoots, management teams step up and buy shares. The fact that no single officer is conducting a transaction tells you all you need to know. They have zero belief in their own ability to execute.
1 · Reply
Latest News on EDSA
Edesa Biotech Reports Fiscal Year 2025 Results

Dec 12, 2025, 4:20 PM EST - 7 weeks ago

Edesa Biotech Reports Fiscal Year 2025 Results

Edesa Biotech Announces Upcoming Conference Schedule

Oct 31, 2025, 4:30 PM EDT - 3 months ago

Edesa Biotech Announces Upcoming Conference Schedule

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Oct 28, 2025, 7:45 AM EDT - 3 months ago

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Aug 8, 2025, 4:35 PM EDT - 6 months ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

May 14, 2025, 4:15 PM EDT - 9 months ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Apr 28, 2025, 4:30 PM EDT - 10 months ago

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech Announces Chief Financial Officer Transition

Apr 4, 2025, 4:15 PM EDT - 10 months ago

Edesa Biotech Announces Chief Financial Officer Transition

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 14, 2025, 4:15 PM EST - 1 year ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Feb 13, 2025, 7:00 AM EST - 1 year ago

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Edesa Biotech Reports Fiscal Year 2024 Results

Dec 13, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2024 Results

Edesa Biotech's Founder Makes Strategic Investment in the Company

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Edesa Biotech's Founder Makes Strategic Investment in the Company

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Sep 13, 2024, 7:38 PM EDT - 1 year ago

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Aug 9, 2024, 4:20 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Jun 24, 2024, 8:20 AM EDT - 1 year ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

May 10, 2024, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Edesa Biotech to Participate in Upcoming Investor Conferences

Apr 2, 2024, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Investor Conferences

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Mar 21, 2024, 4:30 PM EDT - 2 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Mar 7, 2024, 8:45 AM EST - 2 years ago

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Mar 4, 2024, 4:30 PM EST - 2 years ago

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Feb 9, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Jan 4, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Edesa Biotech Reports Fiscal Year 2023 Results

Dec 15, 2023, 4:10 PM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2023 Results

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Nov 20, 2023, 4:05 PM EST - 2 years ago

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Oct 25, 2023, 9:10 AM EDT - 2 years ago

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Oct 12, 2023, 12:15 PM EDT - 2 years ago

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Oct 12, 2023, 12:10 PM EDT - 2 years ago

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Edesa Biotech Announces One-for-Seven Reverse Share Split

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Sep 28, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Aug 9, 2023, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Jul 26, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Jun 28, 2023, 7:55 AM EDT - 2 years ago

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 27, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Jun 15, 2023, 8:00 AM EDT - 2 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

May 11, 2023, 4:30 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Edesa Biotech to Participate in Swiss Biotech Day

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Edesa Biotech to Participate in Swiss Biotech Day

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Apr 4, 2023, 8:45 AM EDT - 3 years ago

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Mar 23, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Mar 15, 2023, 8:10 AM EDT - 3 years ago

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 10, 2023, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Feb 1, 2023, 8:15 AM EST - 3 years ago

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

Jan 17, 2023, 8:30 AM EST - 3 years ago

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Dec 20, 2022, 8:30 AM EST - 3 years ago

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Edesa Biotech Reports Fiscal Year 2022 Results

Dec 16, 2022, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal Year 2022 Results

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Dec 2, 2022, 8:00 AM EST - 3 years ago

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Nov 3, 2022, 9:00 AM EDT - 3 years ago

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Sep 30, 2022, 8:00 AM EDT - 3 years ago

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Sep 8, 2022, 4:30 PM EDT - 3 years ago

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Sep 7, 2022, 8:00 AM EDT - 3 years ago

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Treb3k
Treb3k Feb. 2 at 6:57 PM
$EDSA power hour baby LETS GOOOOOOOOOOO
0 · Reply
Treb3k
Treb3k Feb. 2 at 6:57 PM
$EDSA its par buying on open market! confident in his company
0 · Reply
EdV3
EdV3 Feb. 2 at 6:21 PM
$EDSA looking like one of the tutes sold their commons at any price to get out Would explain the large sells and quick rebound after they completed liquidation Other possibility is company crushed the atm..shelf now tapped so share price can stabilize....hopefully
0 · Reply
Moneyybaggs
Moneyybaggs Feb. 2 at 3:57 PM
$EDSA Understand who might be selling, but who in their RIGHT FOOKIN MIND is buying this steaming pile of excrement?!?
0 · Reply
EdV3
EdV3 Feb. 2 at 3:46 PM
$EDSA Maybe ATM, maybe a tute selling last few days. Good bad or ugly something is gonna happen.
0 · Reply
maurizio58
maurizio58 Feb. 2 at 3:21 PM
$EDSA other 450.000 actions
0 · Reply
maurizio58
maurizio58 Feb. 2 at 3:20 PM
$EDSA ATM...!!!!!!
0 · Reply
EdV3
EdV3 Feb. 1 at 8:21 PM
$EDSA Tough to watch the stock price slide into the depths of hell. Probably will get worse. IMO they will not proceed with dosing patients until a strategic partner is lined up, or there is some clear PIPE type financing ready to go. A realistic partnership could look like a small upfront payment of 3-7m with the partner fully funding the P2. Another route could be a co development deal with a larger upfront payment and cost sharing for the trial. A 3rd possibility would be a regional licensing deal (ex NA) with the partner funding a P2 in their market. Honestly, any of those scenarios are realistic and would make a world of difference for shareholders. A "free" P2 for EB06 would resuscitate interest. In parallel I'm sure they are still trying to probe potential pathways for EB05. It comes down now to execution. 7 years since ipo and they've destroyed basically all the value. With their track record, does anyone truly believe they'll be able to pull it off? Hard to say.
0 · Reply
EdV3
EdV3 Feb. 1 at 8:10 PM
$EDSA My guess is they have around 12 mil in cash as of right this moment. I'm assuming they've sold another 500k-700k shares atm since the mid December update so figure the baby shelf has only another mil or so that can be exercised. That means the immediate dilution threat (not withstanding a financing deal which will probably come) is coming to an end. That's a fairly healthy cash position. For them it's around 2 years of runway not accounting for any scaled r&d spend. They will continue to work on putting together a turnkey P2 package which will likely be ready sometime in April or May. They are probably still waiting on drug substance and will soon after submit the necessary package to the FDA. From there the IND should be approved within 30 days unless anything is flagged.
0 · Reply
EdV3
EdV3 Jan. 30 at 9:20 PM
$EDSA When legit companies undergo these valuation overshoots, management teams step up and buy shares. The fact that no single officer is conducting a transaction tells you all you need to know. They have zero belief in their own ability to execute.
1 · Reply
EdV3
EdV3 Jan. 30 at 9:17 PM
$EDSA If they don't initiate enrollment for the EB06 trial (they aren't going to FYI), they have close to 18-24 months of working capital on the books assuming no incremental R&D spend/scale up. Obviously the goal is to complete the turnkey P2 setup....then what? What's the exit strategy from there? That they haven't elucidated.
0 · Reply
arioch1
arioch1 Jan. 30 at 8:55 PM
$EDSA i guess nasdaq will come knocking soon
0 · Reply
EdV3
EdV3 Jan. 30 at 6:33 PM
$EDSA What they didn't tell you is they yolo'd all their working capital into silver 2 days ago
0 · Reply
ElephantMan101
ElephantMan101 Jan. 30 at 5:29 PM
$EDSA what an embarrassment of a company. R/S again? This will be a life lesson for me
1 · Reply
EdV3
EdV3 Jan. 30 at 5:17 PM
$EDSA Get this fucking guy OUT NOW How in the world does he keep his job?
0 · Reply
EdV3
EdV3 Jan. 30 at 5:13 PM
$EDSA Down 25% since Tuesday....yeah maybe he's right probably some 8k tonight
0 · Reply
EdV3
EdV3 Jan. 30 at 5:09 PM
$EDSA No insider buys LOL????
0 · Reply
EdV3
EdV3 Jan. 30 at 5:06 PM
$EDSA Wow, there you go, it really will be sub $1 in a few minutes.
0 · Reply
maurizio58
maurizio58 Jan. 30 at 5:06 PM
$EDSA BINGO....1,10$
0 · Reply
EdV3
EdV3 Jan. 30 at 4:58 PM
$EDSA That would be amazing - then they can shut down and distribute the remaining cash to shareholders.
0 · Reply
Treb3k
Treb3k Jan. 30 at 4:56 PM
$EDSA tonight they will announce they are withdrawing from the BARDA trial or that they have halted their plans for EB06
0 · Reply
EdV3
EdV3 Jan. 30 at 4:54 PM
$EDSA Pardeep spent too much of his time deep up in those assholes and failed to pay attention to Edesa. Actually that's not even accurate it's really just a fraudulent shell to pay for his whip and draw a bogus salary for him and his goons.
0 · Reply